Pharma

Your Article Summary

See Latest Articles

ARIAD Announces Preliminary Data from Two Ongoing Clinical Trials of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Targeted Drugs
ARIAD Pharmaceuticals, 07/29/09

ARIAD Pharmaceuticals, Inc. announced preliminary findings from two ongoing clinical trials evaluating oral ridaforolimus in combination with trastuzumab in patients with resistant, metastatic breast cancer and with bevacizumab in heavily pretreated patients with refractory, metastatic solid tumors. Abstracts describing these data have been submitted for presentation at major medical meetings to be held later this year. ARIAD is developing ridaforolimus, an investigational mTOR inhibitor, in collaboration with its partner, Merck and Co, Inc.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09

MediciNova and Avigen Stockholders Approve Merger
Avigen, 12/18/09

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

 See all of M&A/Partnerships